Why the study?
Does gemfibrozil reduce the incidence of coronary heart disease in dyslipidemic men?
Population
Dyslipidemic men
Comparison
Gemfibrozil vs Placebo
Design
RCT, Randomized, Double-blind
Follow-up
5 years
Authors
Loading...
Supports gemfibrozil for primary CHD prevention in dyslipidemic men; confirms HDL elevation and LDL reduction as key mechanisms.
Does gemfibrozil reduce the incidence of coronary heart disease in dyslipidemic men?
Gemfibrozil therapy significantly reduces the incidence of coronary heart disease in dyslipidemic men, driven by both the elevation of HDL and the lowering of LDL cholesterol levels.
Vesa Manninen (1988) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: